Lyell Immunopharma, Inc. (LYEL)

Market Cap	287.60M
Revenue (ttm)	63,000
Net Income (ttm)	-203.99M
Shares Out	279.22M
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,652,063
Open	1.090
Previous Close	1.110
Day's Range	0.865 - 1.110
52-Week Range	0.850 - 3.256
Beta	-0.48
Analysts	Sell
Price Target	1.00 (-2.91%)
Earnings Date	Nov 7, 2024

About LYEL

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epige...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 224
• Stock Exchange: NASDAQ
• Ticker Symbol: LYEL
• Website: https://lyell.com

Financial Performance

In 2023, Lyell Immunopharma's revenue was $130,000, a decrease of -99.85% compared to the previous year's $84.68 million. Losses were -$234.63 million, 28.1% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for LYEL stock is "Sell." The 12-month stock price forecast is $1.0, which is a decrease of -2.91% from the latest price.

Price Target

$1.0

(-2.91% downside)

Analyst Consensus: Sell